Integral membrane protein 2A enhances sensitivity to chemotherapy via notch signaling pathway in cervical cancer. Issue 2 (20th December 2021)

• Record Type: Journal Article
• Authors: Li, Yan; Wang, Jianhua; Gao, Chengzhen; Hu, Qiyan; Mao, Xiaogang
• Is Part Of: Bioengineered. Volume 12:Issue 2(2021)
• Page Start: 10183
• Page End: 10193
• Publication Date: 2021-12-20
• Subjects: Cervical cancer -- ITM2A -- cisplatin -- chemotherapy -- resistance -- Notch signaling pathway; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.2001218
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: As the second most common cancer among women, cervical cancer is a huge threat to their health all over the world. Integral membrane protein 2A (ITM2A), a member of the Type II Integral Membrane protein (ITM2) family, has been reported to act as a tumor suppressor in breast cancer and ovarian cancer. Moreover, the low expression of ITM2A was associated with cervical adenocarcinoma. However, the function of ITM2A in drug resistance in cervical cancer remains unclear. Here, we used bioinformatics methods to screen differentially expressed genes (DEGs) closely related to chemotherapeutic relapse cervical carcinoma. ITM2A is downregulated in cervical tumor tissues and is associated with poor survival. Furthermore, ITM2A is also downregulated in cervical cancer cells with cisplatin resistance. Overexpression of ITM2A increases the cisplatin sensitivity of cervical cancer cells. Mechanically, ITM2A upregulation mediates the sensitivity of cervical cancer cell through Notch signaling pathway. Our study suggests that ITM2A may serve as a target in mediating cisplatin-resistant cervical cancer.